Browsing Tag
SCN2A developmental and epileptic encephalopathy
1 post
Could elsunersen become the asset that steadies Praxis Precision Medicines’ CNS pipeline?
Find out how Praxis’ FDA Breakthrough Therapy Designation for elsunersen could affect PRAX stock, rare epilepsy strategy and precision neuroscience today!